NCR1 and cancer: More recently, a first‐in‐class trifunctional agonistic antibody targeting two activating receptors (NKp46 and CD16‐mediated ADCC) and a tumor antigen on cancer cells augmented NK‐mediated tumor killing in preclinical murine models of cancer.48